Comparison and Applicability of Molecular Classifications for Gastric Cancer

GC is a heterogeneous disease, which currently ranks as the fifth most common cancer and the third leading cause of cancer-related death worldwide [1]. Despite many efforts to improve treatment strategies in the last decade, gastric cancer (GC) still presents dismal outcomes. Only 30% of GC are diagnosed at a local stage and the 5-year survival for pTNM stage groups classified according to the 8th edition of the Cancer staging manual of the American Joint Committee on Cancer (AJCC) are between 80 and 68% for stage I, 60 and 46% for stage II, 30 and 8% for stage III and 5% for stage IV, based on data from NCDB (National Cancer Database) Research Unit of the American College of Surgeons [2].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research